Pfizer Inc. CEO Albert Bourla said he has put a disproportionate weight on developing a vaccine for COVID-19 over other pipeline projects given the scope of the global health crisis. The chief executive talked about Pfizer's race to develop a vaccine for COVID-19 during a virtual Harvard Business Review event on 22 June.
"Delaying [by one] month a cancer medicine is terrible for people, but it is not the same [as] delaying two or three months a vaccine solution for COVID that could be saving the world and the economy," Bourla said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?